Completed PHASE2 INTERVENTIONAL 1-arm NCT02599194

18F-FSPG PET/CT for Cancer Patients on Therapy

An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy

Sponsor: Andrei Iagaru

Conditions B-Cell Neoplasm Estrogen Receptor Negative HER2/Neu Negative Metastatic Renal Cell Cancer Progesterone Receptor Negative Stage III Mesothelioma Stage III Renal Cell Cancer Stage IIIA Breast Cancer Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Stage IV Mesothelioma Stage IV Non-Small Cell Lung Cancer Stage IV Renal Cell Cancer Triple-Negative Breast Carcinoma

Interventions 18F-FDG 18F-FSPG

Updated 9 times since 2017 Last updated: Dec 11, 2018 Started: Jul 31, 2015 Primary completion: Dec 14, 2016 Completion: Dec 14, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates B-Cell Neoplasm and Estrogen Receptor Negative and is currently completed. Andrei Iagaru leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Feb 2019 — Jan 2021 [monthly]

Completed PHASE2

Status: Suspended → Completed
Jun 2018 — Feb 2019 [monthly]

Suspended PHASE2
Feb 2017 — Jun 2018 [monthly]

Suspended PHASE2

Status: Recruiting → Suspended
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Andrei Iagaru
National Cancer Institute (NCI)

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States